base metals investing Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
base metals investing Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
base metals investing Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
base metals investing Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
base metals investing Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
base metals investing Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
base metals investing Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
base metals investing Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
base metals investing Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
base metals investing Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
base metals investing Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
base metals investing Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Apex Extends Trinity Zone 200 m with 3.55% REO over 116.0 m and 2.35% over 171.5 m in Western Step-out Drilling at Rift
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property
